查找临床试验
已按「前列腺癌」检索，对应国际通用词 prostate cancer
共找到 223 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 00:19，每 5 分钟自动同步99mTc-P137 SPECT/CT in Prostate Cancer
China
年龄 18 Years – 不限
First Affiliated Hospital Xi'an Jiaotong University
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
United States、China
年龄 18 Years – 不限
Shenzhen Ionova Life Sciences Co., Ltd.
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
United States、Canada、Czechia、Denmark、France 等 11 国
年龄 18 Years – 不限
Novartis Pharmaceuticals
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
United States、Australia、Brazil、Canada、Chile 等 12 国
年龄 18 Years – 不限
Merck Sharp & Dohme LLC
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
United States、China
年龄 18 Years – 不限
Zenith Epigenetics
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
China
年龄 40 Years – 不限
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy
China
年龄 18 Years – 75 Years
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
United States、Argentina、Australia、Austria、Belgium 等 12 国
年龄 18 Years – 100 Years
Novartis Pharmaceuticals
68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk
Taiwan
年龄 40 Years – 85 Years
Chang Gung Memorial Hospital
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
United States、China
年龄 18 Years – 不限
Janssen Research & Development, LLC
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
China
年龄 18 Years – 不限
FindCure Biosciences (ZhongShan) Co., Ltd.
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
China
年龄 18 Years – 85 Years
Jiangsu HengRui Medicine Co., Ltd.